Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 7/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.74 |
| ▸ | PGR | P06401 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 7/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | AR | P10275 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.68 |
| ▸ | BLM | P54132 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946610 | 1.00 | SHBG (0.74) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL634733 | 1.00 | SHBG (0.74) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL140769 | 0.91 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL11730925 | 0.91 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL8846971 | 0.91 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Topterone SCHEMBL3844149 | 0.91 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL11728942 | 0.89 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL10393805 | 0.89 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL8236612 | 0.89 | SHBG (0.68) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| SCHEMBL29437217 | 0.88 | SHBG (0.71) | SHBGNR3C1PGRALDH1A1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-08-21 | — | — | US | disclosed |
| US-8748177-B2 | Compositions for proliferation of cells and related methods | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-06-10 | — | — | US | disclosed |
| EP-2598150-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | The Hospital For Sick Children (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012018643-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-09 | — | — | WO | disclosed |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20100092463-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-04-15 | — | — | US | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
| US-20100061976-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-03-11 | — | — | US | disclosed |
| US-20100035855-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-11 | — | — | US | disclosed |
| US-20100022494-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022487-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022991-A1 | System and device for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022497-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022488-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022489-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100023344-A1 | System and device for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| EP-1135139-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033847-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | SHBG 1806/4885NR3C1 3193/4885PGR 1770/4885 |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | SHBG 1806/4885NR3C1 3193/4885PGR 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.